Equillium (0FY) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Eq504 | Ulcerative Colitis | Phase I | Not Yet Recruiting | A Phase I, Randomized, Double-Blind, Placebo-Controlled Study of EQ504 in Single and Multiple Ascending Doses in Healthy Volunteers | Oct 06, 2026 | ― |
| Eq101 | Alopecia Areata, Alopecia, Alopecia Totalis, Alopecia Universalis | Phase II | Completed | Study of EQ101 in Adult Subjects With Moderate to Severe Alopecia Areata | Oct 13, 2022 | ― |
| Itolizumab | Acute-Graft-Versus-Host Disease, Graft Versus Host Disease, Agvhd, Gvhd, Acute Gvhd | Phase III | Terminated | A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR) | Oct 01, 2021 | ― |
| Eq001 | Coronavirus | Phase III | Withdrawn | A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19 | Oct 21, 2020 | ― |
| Itolizumab [Bmab 600] | Lupus Nephritis, Lupus Erythematosus | Phase I | Completed | Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis | Sep 30, 2019 | ― |
| Eq001 | Asthma | Phase I | Completed | A Study of Itolizumab (EQ001) to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity in Uncontrolled Asthma | Jun 27, 2019 | ― |
| Eq001 | Acute-Graft-Versus-Host Disease, Agvhd, Gvhd, Gvhd, Acute | phase1AndPhase2 | Completed | A Study to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity of EQ001 in Subjects With aGVHD | Nov 19, 2018 | ― |
| Normal Saline, Bnz-1 | Alopecia Areata, Alopecia Totalis, Alopecia Universalis | Phase II | Withdrawn | Phase 2 Trial of BNZ-1 in Patients With Moderate to Severe Alopecia Areata | May 10, 2018 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Eq504 | Phase I | Ulcerative Colitis | Not Yet Recruiting | A Phase I, Randomized, Double-Blind, Placebo-Controlled Study of EQ504 in Single and Multiple Ascending Doses in Healthy Volunteers | Oct 06, 2026 | ― |
| Eq101 | Phase II | Alopecia Areata, Alopecia, Alopecia Totalis, Alopecia Universalis | Completed | Study of EQ101 in Adult Subjects With Moderate to Severe Alopecia Areata | Oct 13, 2022 | ― |
| Itolizumab | Phase III | Acute-Graft-Versus-Host Disease, Graft Versus Host Disease, Agvhd, Gvhd, Acute Gvhd | Terminated | A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR) | Oct 01, 2021 | ― |
| Eq001 | Phase III | Coronavirus | Withdrawn | A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19 | Oct 21, 2020 | ― |
| Itolizumab [Bmab 600] | Phase I | Lupus Nephritis, Lupus Erythematosus | Completed | Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis | Sep 30, 2019 | ― |
| Eq001 | Phase I | Asthma | Completed | A Study of Itolizumab (EQ001) to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity in Uncontrolled Asthma | Jun 27, 2019 | ― |
| Eq001 | phase1AndPhase2 | Acute-Graft-Versus-Host Disease, Agvhd, Gvhd, Gvhd, Acute | Completed | A Study to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity of EQ001 in Subjects With aGVHD | Nov 19, 2018 | ― |
| Normal Saline, Bnz-1 | Phase II | Alopecia Areata, Alopecia Totalis, Alopecia Universalis | Withdrawn | Phase 2 Trial of BNZ-1 in Patients With Moderate to Severe Alopecia Areata | May 10, 2018 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Equillium (DE:0FY) have in its pipeline
Equillium DE:0FY is currently developing the following drugs: Eq504, Eq101, Itolizumab, Eq001, Itolizumab [Bmab 600], Normal Saline, Bnz-1. These drug candidates are in various stages of clinical development as the company works toward FDA approval.